Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun Pharma gets US nod for diabetes drug ANDA

MUMBAI: Sun Pharma announced that the US FDA has granted its subsidiary final approval for its abbreviated new drug application for generic version of diabetes drug Prandin. Repaglinide tablets, 1mg and 2mg are therapeutic equivalents of Novo Nordisk's Prandin.

These tablets have annual sales of approximately $200 million in the US. Sun Pharma's subsidiary, being the first-to-file an ANDA for generic Prandin with a para IV certification, is eligible for a 180-day marketing exclusivity in the US, a statement said.